
Amazon’s Trainium AI chips—initially launched for AWS in 2022 and upgraded to Trainium2 (2024) and Trainium3 (2025)—could begin selling to third-party customers, potentially pressuring Nvidia’s data-center dominance. The article argues Amazon (and peers like Microsoft and Google) may match rack-level performance via system-level stacking (144 Trainium3 chips in UltraServers) while lowering costs, though Nvidia’s CUDA/software moat and optimized model ecosystem are expected to limit near-term impact. Net: a longer-term competitive threat to Nvidia, but demand for Nvidia GPUs reportedly still outstrips supply.
The real market mechanism is not "chip share loss" but margin reallocation inside the AI stack. If hyperscalers can package custom silicon into external offerings, the economic rent shifts from merchant GPUs toward cloud platforms that control provisioning, software, and distribution; that is structurally bullish for AMZN/GOOG/MSFT and only secondarily negative for NVDA.
Near term, this is mostly narrative risk for NVDA rather than a cash-flow problem. CUDA lock-in and software migration costs mean the first 6-12 months should look like coexistence, not substitution; any selloff on this theme is more likely a multiple event than an earnings event. The better tell is whether these companies begin disclosing meaningful third-party demand or improved inference economics in 1-3 quarters.
The contrarian take is that the market may be underestimating how much custom silicon strengthens hyperscaler moats. External chip sales are likely to be bundled with cloud consumption, which can reduce customer churn and improve unit economics even if standalone chip margins are mediocre. The main falsifier for the bearish NVDA angle is another period of supply-constrained demand plus Blackwell-led reacceleration; in that case, disintermediation remains years away, not months.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
neutral
Sentiment Score
-0.05
Ticker Sentiment